1. Home
  2. MIRM vs TPH Comparison

MIRM vs TPH Comparison

Compare MIRM & TPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • TPH
  • Stock Information
  • Founded
  • MIRM 2018
  • TPH 2009
  • Country
  • MIRM United States
  • TPH United States
  • Employees
  • MIRM N/A
  • TPH N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • TPH Homebuilding
  • Sector
  • MIRM Health Care
  • TPH Consumer Discretionary
  • Exchange
  • MIRM Nasdaq
  • TPH Nasdaq
  • Market Cap
  • MIRM 3.3B
  • TPH 2.8B
  • IPO Year
  • MIRM 2019
  • TPH N/A
  • Fundamental
  • Price
  • MIRM $67.93
  • TPH $34.94
  • Analyst Decision
  • MIRM Strong Buy
  • TPH Buy
  • Analyst Count
  • MIRM 9
  • TPH 6
  • Target Price
  • MIRM $73.89
  • TPH $42.00
  • AVG Volume (30 Days)
  • MIRM 661.2K
  • TPH 1.3M
  • Earning Date
  • MIRM 08-06-2025
  • TPH 07-24-2025
  • Dividend Yield
  • MIRM N/A
  • TPH N/A
  • EPS Growth
  • MIRM N/A
  • TPH N/A
  • EPS
  • MIRM N/A
  • TPH 3.96
  • Revenue
  • MIRM $429,161,000.00
  • TPH $4,041,885,000.00
  • Revenue This Year
  • MIRM $36.76
  • TPH N/A
  • Revenue Next Year
  • MIRM $17.48
  • TPH $1.28
  • P/E Ratio
  • MIRM N/A
  • TPH $8.83
  • Revenue Growth
  • MIRM 62.33
  • TPH N/A
  • 52 Week Low
  • MIRM $36.86
  • TPH $27.90
  • 52 Week High
  • MIRM $69.00
  • TPH $46.91
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 82.95
  • TPH 61.11
  • Support Level
  • MIRM $50.25
  • TPH $32.41
  • Resistance Level
  • MIRM $67.45
  • TPH $35.97
  • Average True Range (ATR)
  • MIRM 2.89
  • TPH 1.00
  • MACD
  • MIRM 1.38
  • TPH 0.29
  • Stochastic Oscillator
  • MIRM 94.29
  • TPH 81.96

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About TPH Tri Pointe Homes Inc.

Tri Pointe Homes Inc is an American construction company that focuses on residential construction. The company is engaged in the design, construction, and sale of single-family attached and detached homes in different states across the United States. Its operations are organized into two principal businesses: homebuilding. which generates key revenue, and financial services. The homebuilding business has three reportable operating segments, based on the geographical layout of the markets, and includes West region, Central region, and East region. The company's financial services operation is comprised of its Tri Pointe Connect mortgage financing operations, Tri Pointe Assurance title and escrow services operations, and Tri Pointe Advantage property and casualty insurance agency operations.

Share on Social Networks: